Dermatology

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 notable dermatology updates from the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.

This analysis highlights the risk of superficial fungal infections among patients with moderate-to-severe psoriasis given biologics such as IL-17 inhibitors.

This update by FDA officials extends the review period for ruxolitinib cream as a treatment for atopic dermatitis in children aged 2-11 years.

These data from RAD 2025 highlight upadacitinib’s efficacy in the phase 3 Measure Up 1 and 2 studies for older adults with atopic dermatitis.

This Q&A interview at RAD 2025 features a discussion about a talk titled ‘Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis.’

Dupilumab (Dupixent) approved as the first targeted therapy for bullous pemphigoid, marking 8th indication for diseases with type 2 inflammation.

Melinda Gooderham, MD, MSc, joins The Medical Sisterhood to discuss balancing mentorship, leadership, and family, as well as the empowerment of women in the medical field.

This analysis highlights the observed risk of developing psoriasis when using dupilumab to treat atopic dermatitis.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This June 17, 2025 SOCS News Update highlights creating strategic plans with mentors and mentees.

The FDA-cleared DermaSensor shows promise for skin cancer detection in primary care.

Recent research comparing the two diseases against a sample of the general population has indicated a substantially higher mortality risk and rate in GPP than in plaque psoriasis.

These data highlight the adverse events resulting from the use of dutasteride and finasteride in treating androgenetic alopecia.

Study findings highlight a heightened risk of MetS in patients with psoriasis, especially those with more severe disease based on PASI scores.

Research has indicated a suggestive association between predicted psoriasis and uterine corpus cancer in women and prostate cancer in men.

This interview at RAD 2025 highlights a session on dose flexibility in adult patients with atopic dermatitis, presented by Tejesh Patel, MD.

A high alopecia areata burden was seen among US Asian and Pacific Islander children, particularly South Asian, Filipino, Vietnamese, and Native Hawaiian/Pacific Islander subgroups.

This Q&A interview with Lisa Swanson, MD, features a discussion of the highlights of Swanson’s talk at RAD 2025 regarding pediatric atopic dermatitis.

In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.

These data suggest that smoking history did not impact rates of malignancy, MACE, and VTE among those with atopic dermatitis treated with upadacitinib.

In this Q&A interview at RAD 2025, Tiffany Mayo, MD, highlights the biggest takeaways from her talk on complex cases in atopic dermatitis and hair loss.